PT  - JOURNAL ARTICLE
AU  - Noha Althubaity
AU  - Julia Schubert
AU  - Daniel Martins
AU  - Tayyabah Yousaf
AU  - Maria A. Nettis
AU  - Valeria Mondelli
AU  - Carmine Pariante
AU  - Neil A. Harrison
AU  - Edward T. Bullmore
AU  - Danai Dima
AU  - Federico E. Turkheimer
AU  - Mattia Veronese
AU  - the NIMA Consortium
TI  - Choroid plexus enlargement is associated with neuroinflammation and reduction of blood brain barrier permeability in depression
AID  - 10.1101/2021.09.30.21264226
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.09.30.21264226
4099  - http://medrxiv.org/content/early/2021/10/01/2021.09.30.21264226.short
4100  - http://medrxiv.org/content/early/2021/10/01/2021.09.30.21264226.full
AB  - Background Recent studies have shown that choroid plexuses (CP) may be involved in the neuro-immune axes, playing a role in the interaction between the central and peripheral inflammation. Here we aimed to investigate CP volume alterations in depression and their associations with inflammation.Methods 51 depressed participants (HDRS score >13) and 25 age- and sex-matched healthy controls (HCs) from the Wellcome Trust NIMA consortium were re-analysed for the study. All the participants underwent full peripheral cytokine profiling and simultaneous [11C]PK11195 PET/structural MRI imaging for measuring neuroinflammation and CP volume respectively.Results We found a significantly greater CP volume in depressed subjects compared to HCs (t(76) = +2.17) that was positively correlated with [11C]PK11195 PET binding in the anterior cingulate cortex (r=0.28, p=0.02), prefrontal cortex (r=0.24, p=0.04), and insular cortex (r=0.24, p=0.04), but not with the peripheral inflammatory markers: CRP levels (r=0.07, p=0.53), IL-6 (r=-0.08, p=0.61), and TNF-α (r=-0.06, p=0.70). The CP volume correlated with the [11C]PK11195 PET binding in CP (r=0.34, p=0.005). Integration of transcriptomic data from the Allen Human Brain Atlas with the brain map depicting the correlations between CP volume and PET imaging found significant gene enrichment for several pathways involved in neuroinflammatory response.Conclusion This result supports the hypothesis that changes in brain barriers may cause reduction in solute exchanges between blood and CSF, disturbing the brain homeostasis and ultimately contributing to inflammation in depression. Given that CP anomalies have been recently detected in other brain disorders, these results may not be specific to depression and might extend to other conditions with a peripheral inflammatory component.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe BIODEP study was sponsored by the Cambridgeshire and Peterborough NHS Foundation Trust and the University of Cambridge and funded by a strategic award from the Wellcome Trust (104025) in partnership with Janssen GlaxoSmithKline Lundbeck and Pfizer Additional funding was provided by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and Kings College London and by the NIHR Cambridge Biomedical Research Centre (Mental Health)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Written informed consent was obtained from all individual participants included in the studies. The BIODEP study was approved by the NRES Committee East of England Cambridge Central (REC reference:15/EE/0092) and the UK Administration of Radioactive Substances Advisory Committee.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request and upon approval from the research consortia.The dataset is part of "Biomarkers in Depression (BIODEP) study, NIMA consortium, https://www.neuroimmunology.org.uk/. https://www.neuroimmunology.org.uk/